
According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
In September, our table of the month focuses on questions you should ask female patients before aesthetic procedures and also which red flags to look for to make sure you know when not treat.
Links to PDF






